文献速递消化道肿瘤与早癌消化内镜

用于检测早发性结直肠癌患者的液体活检特征

A Liquid Biopsy Signature for the Detection of Patients With Early-Onset Colorectal Cancer.
PubMed 文献 · Gastroenterology · 2022-07-16

本研究通过分析公开非编码RNA表达数据集筛选循环microRNA特征,并在两个独立队列(早发性结直肠癌患者149例、对照110例)及22例术前术后血浆标本中验证。4种miRNA组合(miR-193a-5p、miR-210、miR-513a-5p、miR-628-3p)在训练队列中识别早发性结直肠癌的曲线下面积为0.92(95%CI 0.85-0.96),验证队列为0.88(95%CI 0.82-0.93),并能稳健识别早期患者(P < .001)。

要点

  • 4种miRNA组合在训练队列识别早发性结直肠癌的AUC为0.92(95%CI 0.85-0.96)。
  • 该面板在独立验证队列的AUC为0.88(95%CI 0.82-0.93)。
  • 该面板可稳健识别早期早发性结直肠癌患者(P < .001)。

核心结论

  • 新型miRNA特征有潜力以高准确度识别早发性结直肠癌患者,可用于该病的无创诊断。

研究设计与样本

  • 系统发现阶段分析大型公开非编码RNA表达数据集(GSE115513),筛选出miRNA面板。
  • 在2个独立队列中验证:早发性结直肠癌患者149例与对照110例,另检测22例术前术后血浆标本。
  • 采用定量逆转录聚合酶链反应测定。

主要发现

  • 发现阶段鉴定出4种在血液样本中表达的miRNA:miR-193a-5p、miR-210、miR-513a-5p和miR-628-3p。
  • 训练队列中该4种miRNA组合识别早发性结直肠癌的AUC为0.92(95%CI 0.85-0.96)。
  • 独立验证队列中AUC为0.88(95%CI 0.82-0.93)。
  • 该miRNA面板可稳健识别早期早发性结直肠癌患者(P < .001)。
  • 术后血浆标本中miRNA表达降低,提示其肿瘤特异性。

关键数值与推荐

  • 训练队列:4种miRNA组合识别早发性结直肠癌的AUC 0.92(95%CI 0.85-0.96)。
  • 验证队列:同一面板识别早发性结直肠癌的AUC 0.88(95%CI 0.82-0.93)。
  • 早期早发性结直肠癌识别:P < .001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Early-onset colorectal cancer (EOCRC) is a distinct clinical and molecular entity with poor survival outcomes compared with late-onset CRC. Although the incidence of EOCRC is rising, current CRC screening strategies have several limitations in diagnostic performance for EOCRC. In view of this clinical challenge, novel and robust biomarkers for detection of EOCRC are necessary. The aim of this study was to develop a circulating micro RNA (miRNA) signature for the diagnosis of patients with EOCRC. METHODS: A systematic discovery approach by analyzing a large, publicly available, noncoding RNA expression profiling dataset (GSE115513) was used. A panel of miRNAs was identified, which was subsequently validated in blood samples from patients with EOCRC in 2 independent cohorts (n = 149) compared with controls (n = 110) and pre/postoperative plasma specimens (n = 22) using quantitative reverse-transcription polymerase chain reaction assays. RESULTS: In the discovery phase, 4 miRNAs were found to be expressed in blood samples. A combination signature of these 4 miRNAs (miR-193a-5p, miR-210, miR-513a-5p, and miR-628-3p) yielded an area under the curve of 0.92 (95% confidence interval, 0.85-0.96) for identification of EOCRC in the training cohort. The miRNA panel performance was then confirmed in an independent validation cohort (area under the curve, 0.88; 95% confidence interval, 0.82-0.93). Moreover, the miRNA panel robustly identified patients with early-stage EOCRC (P < .001). The decreased expression of miRNAs in postsurgery plasma specimens indicated their tumor specificity. CONCLUSIONS: Our novel miRNA signature for the diagnosis of EOCRC has the potential to identify patients with EOCRC with high accuracy for clinical application in the noninvasive diagnosis of EOCRC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Nakamura K, Hernández G, Sharma GG, et al. A Liquid Biopsy Signature for the Detection of Patients With Early-Onset Colorectal Cancer. Gastroenterology. 2022. PMID: 35850198. doi:10.1053/j.gastro.2022.06.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。